JP2004532868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532868A5 JP2004532868A5 JP2002592925A JP2002592925A JP2004532868A5 JP 2004532868 A5 JP2004532868 A5 JP 2004532868A5 JP 2002592925 A JP2002592925 A JP 2002592925A JP 2002592925 A JP2002592925 A JP 2002592925A JP 2004532868 A5 JP2004532868 A5 JP 2004532868A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- aryl
- independently
- coor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 459
- 125000003118 aryl group Chemical group 0.000 claims 180
- 125000003545 alkoxy group Chemical group 0.000 claims 76
- 125000001424 substituent group Chemical group 0.000 claims 73
- 229910052739 hydrogen Inorganic materials 0.000 claims 72
- 125000003107 substituted aryl group Chemical group 0.000 claims 66
- 239000001257 hydrogen Substances 0.000 claims 64
- -1 R 7 -Benzyl Chemical group 0.000 claims 57
- 239000000203 mixture Substances 0.000 claims 51
- 125000001072 heteroaryl group Chemical group 0.000 claims 48
- 125000002947 alkylene group Chemical group 0.000 claims 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 40
- 125000005843 halogen group Chemical group 0.000 claims 37
- 150000002431 hydrogen Chemical class 0.000 claims 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 32
- 238000006467 substitution reaction Methods 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 30
- 239000011780 sodium chloride Substances 0.000 claims 30
- 239000012453 solvate Substances 0.000 claims 30
- 229910052736 halogen Inorganic materials 0.000 claims 29
- 150000002367 halogens Chemical class 0.000 claims 29
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 24
- 125000004432 carbon atoms Chemical group C* 0.000 claims 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 24
- 125000003003 spiro group Chemical group 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000002541 furyl group Chemical group 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 125000002883 imidazolyl group Chemical group 0.000 claims 16
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 16
- 125000002757 morpholinyl group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 125000003386 piperidinyl group Chemical group 0.000 claims 16
- 125000003226 pyrazolyl group Chemical group 0.000 claims 16
- 125000004076 pyridyl group Chemical group 0.000 claims 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 16
- 125000000168 pyrrolyl group Chemical group 0.000 claims 16
- 125000000335 thiazolyl group Chemical group 0.000 claims 16
- 125000001544 thienyl group Chemical group 0.000 claims 16
- 125000004450 alkenylene group Chemical group 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 12
- 125000002993 cycloalkylene group Chemical group 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 125000000842 isoxazolyl group Chemical group 0.000 claims 12
- 125000001624 naphthyl group Chemical group 0.000 claims 12
- 125000002971 oxazolyl group Chemical group 0.000 claims 12
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 12
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 12
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 claims 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 9
- 206010001897 Alzheimer's disease Diseases 0.000 claims 9
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 9
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 9
- URSPTJYSBTXILH-UHFFFAOYSA-N 1-methylidenepiperazin-1-ium-4-ide Chemical group C=[N+]1CC[N-]CC1 URSPTJYSBTXILH-UHFFFAOYSA-N 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000004414 alkyl thio group Chemical group 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 125000004104 aryloxy group Chemical group 0.000 claims 8
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 8
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 8
- 125000005879 dioxolanyl group Chemical group 0.000 claims 8
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 8
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 125000001786 isothiazolyl group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 8
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 8
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 7
- 230000000051 modifying Effects 0.000 claims 7
- 210000004369 Blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 210000004556 Brain Anatomy 0.000 claims 5
- 239000000018 receptor agonist Substances 0.000 claims 5
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 claims 4
- 108010025628 Apolipoproteins E Proteins 0.000 claims 4
- 102000013918 Apolipoproteins E Human genes 0.000 claims 4
- 229940107161 Cholesterol Drugs 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 4
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims 4
- 125000000676 alkoxyimino group Chemical group 0.000 claims 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000005336 allyloxy group Chemical group 0.000 claims 4
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 4
- 125000002047 benzodioxolyl group Chemical class O1OC(C2=C1C=CC=C2)* 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 4
- 150000002829 nitrogen Chemical group 0.000 claims 4
- 229920000728 polyester Polymers 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 230000001105 regulatory Effects 0.000 claims 4
- 125000004306 triazinyl group Chemical group 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 208000006752 Brain Edema Diseases 0.000 claims 2
- 102100005531 MAPK8 Human genes 0.000 claims 2
- 101710029924 MAPK8 Proteins 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000037348 biosynthesis Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 1
- 239000003140 4 aminobutyric acid A receptor blocking agent Substances 0.000 claims 1
- 239000003412 4 aminobutyric acid B receptor blocking agent Substances 0.000 claims 1
- 102000003678 AMPA Receptors Human genes 0.000 claims 1
- 108090000078 AMPA Receptors Proteins 0.000 claims 1
- 102100017796 APP Human genes 0.000 claims 1
- 108060000460 APP Proteins 0.000 claims 1
- 229960004373 Acetylcholine Drugs 0.000 claims 1
- 206010002368 Anger Diseases 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 1
- 102100004554 CAST Human genes 0.000 claims 1
- 102100015725 CRHBP Human genes 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 229960001231 Choline Drugs 0.000 claims 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N Docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 1
- 201000010374 Down syndrome Diseases 0.000 claims 1
- 101700057458 Drice Proteins 0.000 claims 1
- 239000003691 GABA modulator Substances 0.000 claims 1
- 101700002119 GAL Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102100002512 HTR1A Human genes 0.000 claims 1
- 108060003344 HTR1A Proteins 0.000 claims 1
- 102000009032 Imidazoline Receptors Human genes 0.000 claims 1
- 108010049134 Imidazoline Receptors Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 claims 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 claims 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 1
- 229960002965 Pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 108010036933 Presenilin-1 Proteins 0.000 claims 1
- 102000012412 Presenilin-1 Human genes 0.000 claims 1
- 108010036908 Presenilin-2 Proteins 0.000 claims 1
- 102000012419 Presenilin-2 Human genes 0.000 claims 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N Probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 1
- 102000016983 Releasing hormones receptors Human genes 0.000 claims 1
- 108070000025 Releasing hormones receptors Proteins 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 108010085012 Steroid Receptors Proteins 0.000 claims 1
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 1
- 108010012715 Superoxide Dismutase Proteins 0.000 claims 1
- 102000011923 Thyrotropin Human genes 0.000 claims 1
- 108010061174 Thyrotropin Proteins 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 claims 1
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 claims 1
- 229940088594 Vitamin Drugs 0.000 claims 1
- 101710010406 ZBP14 Proteins 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 230000002730 additional Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive Effects 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 102000004305 alpha adrenergic receptors Human genes 0.000 claims 1
- 108090000861 alpha adrenergic receptors Proteins 0.000 claims 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1H-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 claims 1
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 claims 1
- 239000002439 beta secretase inhibitor Substances 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 108010079785 calpain inhibitors Proteins 0.000 claims 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 claims 1
- 229940121376 cannabinoid receptor agonists Drugs 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- 230000003196 chaotropic Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 102000027751 corticosteroid receptors Human genes 0.000 claims 1
- 108091008045 corticosteroid receptors Proteins 0.000 claims 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 claims 1
- 108010083720 corticotropin releasing factor-binding protein Proteins 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 150000002194 fatty esters Chemical class 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 230000000407 monoamine reuptake Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 239000008239 natural water Substances 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 229940096700 plain lipid modifying drugs Fibrates Drugs 0.000 claims 1
- 235000002378 plant sterols Nutrition 0.000 claims 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 1
- 229960003912 probucol Drugs 0.000 claims 1
- 239000003649 prolyl endopeptidase inhibitor Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 229940121649 protein inhibitors Drugs 0.000 claims 1
- 239000003881 protein kinase c inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 1
- 239000003982 sigma receptor ligand Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 102000005969 steroid hormone receptors Human genes 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 0 N=CNC1=*C1 Chemical compound N=CNC1=*C1 0.000 description 6
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29365101P | 2001-05-25 | 2001-05-25 | |
US32391101P | 2001-09-21 | 2001-09-21 | |
PCT/US2002/016306 WO2002096415A2 (en) | 2001-05-25 | 2002-05-22 | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004532868A JP2004532868A (ja) | 2004-10-28 |
JP2004532868A5 true JP2004532868A5 (US07560449-20090714-C00011.png) | 2006-01-05 |
Family
ID=26968071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002592925A Pending JP2004532868A (ja) | 2001-05-25 | 2002-05-22 | アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用 |
Country Status (14)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2290562T3 (es) * | 2001-01-26 | 2008-02-16 | Schering Corporation | Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares. |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
EP1429756B1 (en) * | 2001-09-21 | 2006-11-22 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
AU2003218004A1 (en) * | 2002-03-12 | 2003-09-29 | Merck & Co., Inc. | Drug combination therapy |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
WO2004028470A2 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
US7208486B2 (en) * | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7244739B2 (en) * | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
DK1628663T3 (da) | 2003-05-15 | 2010-03-08 | Roskamp Res Llc | Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
US20080260717A1 (en) * | 2003-10-31 | 2008-10-23 | Trustees Of Columbia University In The City Of New York | Methods for Reducing Seizure-Induced Neuronal Damage |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
GB0419124D0 (en) | 2004-08-27 | 2004-09-29 | Proteome Sciences Plc | Methods and compositions relating to Alzheimer's disease |
GB0423356D0 (en) * | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
EP1893570A4 (en) * | 2005-06-22 | 2009-12-23 | Reddy Manne Satynarayana | IMPROVED PROCESS FOR THE PREPARATION OF EZETIMIBE |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
US20070049748A1 (en) * | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
WO2007103453A1 (en) * | 2006-03-06 | 2007-09-13 | Teva Pharmaceutical Industries Ltd. | Ezetimibe compositions |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
CN101641013B (zh) * | 2007-01-22 | 2014-07-30 | Gtx公司 | 核受体结合剂 |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
GB0708507D0 (en) * | 2007-05-02 | 2007-06-13 | Queen Mary & Westfield College | Substituted phosphonates and their use |
CA2701620C (en) | 2007-10-05 | 2014-12-09 | Alzheimer's Institute Of America, Inc. | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
US20130267533A1 (en) * | 2012-04-04 | 2013-10-10 | Fabre-Kramer Pharmaceuticals, Inc. | 5ht1a agonists for treatment of high cholesterol |
PT3413870T (pt) * | 2016-02-11 | 2021-09-10 | Sigmathera Sas | Igmesina para utilização no tratamento de doença de alzheimer |
US11135180B2 (en) * | 2016-03-15 | 2021-10-05 | Rush University Medical Center | Composition and methods for stimulating clearance of amyloid-beta protein |
US20210255202A1 (en) | 2018-06-13 | 2021-08-19 | Michael R. D'Andrea | Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1286A (en) * | 1839-08-13 | Richard else | ||
US2809194A (en) * | 1957-10-08 | Thiadiazine type natriuretic agents | ||
US3108097A (en) * | 1963-10-22 | Ehnojs | ||
NL108640C (US07560449-20090714-C00011.png) * | 1958-05-07 | |||
NL127065C (US07560449-20090714-C00011.png) * | 1964-04-22 | |||
NL137318C (US07560449-20090714-C00011.png) * | 1964-06-09 | |||
US3716583A (en) * | 1969-04-16 | 1973-02-13 | Sumitomo Chemical Co | Phenoxy carboxylic acid derivative |
US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (de) * | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
US4148923A (en) * | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US3948973A (en) * | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
JPS5195049A (en) * | 1975-02-12 | 1976-08-20 | * **********so*****no***tsu*****************************************ni*no | |
US4179515A (en) * | 1975-02-12 | 1979-12-18 | Orchimed S. A. | Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition |
US4235896A (en) * | 1975-02-12 | 1980-11-25 | Orchimed S.A. | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same |
US4075000A (en) * | 1975-05-27 | 1978-02-21 | Eli Lilly And Company | Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones |
US4472309A (en) * | 1975-10-06 | 1984-09-18 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4304718A (en) * | 1975-10-06 | 1981-12-08 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4576753A (en) * | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
US4166907A (en) * | 1976-11-01 | 1979-09-04 | E. R. Squibb & Sons, Inc. | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity |
US4144232A (en) * | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
FR2403078A1 (fr) * | 1977-09-19 | 1979-04-13 | Lafon Labor | Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic |
IT1157365B (it) * | 1977-10-24 | 1987-02-11 | Sandoz Ag | Medicamenti per trattare l'obesita' o ridurre il peso del corpo |
US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4375475A (en) * | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4260743A (en) * | 1979-12-31 | 1981-04-07 | Gist-Brocades N.V. | Preparation of β-lactams and intermediates therefor |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DE3107100A1 (de) * | 1981-02-20 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
US4500456A (en) * | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
US4784734A (en) * | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
US4602005A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
US4534786A (en) * | 1982-06-23 | 1985-08-13 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4443372A (en) * | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4595532A (en) * | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
CA1256650A (en) * | 1983-03-25 | 1989-06-27 | Toshinari Tamura | Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds |
US4614614A (en) * | 1983-03-28 | 1986-09-30 | Ciba-Geigy Corporation | Process for the manufacture of optically active azetidinones |
US4675399A (en) * | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
WO1985004876A1 (en) * | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
US4576749A (en) * | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229510A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
US5229381A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US4654362A (en) * | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
FR2561916B1 (fr) * | 1984-03-30 | 1987-12-11 | Lafon Labor | Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau |
US4581170A (en) * | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4633017A (en) * | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4576748A (en) * | 1984-09-17 | 1986-03-18 | Merck & Co., Inc. | 3-Hydroxy-3-aminoethyl β-lactams |
US4620867A (en) * | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
US4642903A (en) * | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
DE3787815T2 (de) * | 1986-02-19 | 1994-03-24 | Sanraku Inc | Azetidinonderivate. |
GB8607312D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
FR2598146B1 (fr) * | 1986-04-30 | 1989-01-20 | Rech Ind | Nouveau procede de preparation de fibrates. |
DE3621861A1 (de) * | 1986-06-30 | 1988-01-14 | Laszlo Dr Med Ilg | Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen |
FR2602423B1 (fr) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
US4814354A (en) * | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
US5229362A (en) * | 1986-12-15 | 1993-07-20 | Eli Lilly And Company | Antibiotic A10255 complex and factors, and process and production therefor |
ZA879415B (en) * | 1986-12-15 | 1989-08-30 | Lilly Co Eli | Antibiotic a10255 complex and factors,microorganisms,process and production therefor |
JPS63156788A (ja) * | 1986-12-22 | 1988-06-29 | Sanraku Inc | 光学活性アゼチジノン類 |
US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
EP0288973B1 (en) * | 1987-04-28 | 1993-01-13 | Fujisawa Astra Ltd. | Benzothiazolinone derivatives, their production and pharmaceutical composition |
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US5091525A (en) * | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US4834846A (en) * | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
DE3807895A1 (de) * | 1988-03-10 | 1989-09-21 | Knoll Ag | Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker |
GB8813012D0 (en) * | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
US4952689A (en) * | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US4876365A (en) * | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
FR2640621B1 (fr) * | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
JPH03108490A (ja) * | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | フォスフォリパーゼa↓2阻害物質 |
US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
JP2640986B2 (ja) * | 1990-11-08 | 1997-08-13 | 高砂香料工業株式会社 | (1′r,3s)―3―(1′―ヒドロキシエチル)―アゼチジン―2―オン又はその誘導体の製造法 |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
JP3144624B2 (ja) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
JP2000505063A (ja) * | 1995-12-08 | 2000-04-25 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 |
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
HUP9901359A3 (en) * | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
DE69833971T2 (de) * | 1998-01-28 | 2006-11-02 | Warner-Lambert Co. Llc | Verfahren zur behandlung der alzheimerschen krankheit |
-
2002
- 2002-05-22 DE DE60216275T patent/DE60216275T2/de not_active Expired - Fee Related
- 2002-05-22 AU AU2002308778A patent/AU2002308778A1/en not_active Abandoned
- 2002-05-22 CA CA002447884A patent/CA2447884A1/en not_active Abandoned
- 2002-05-22 WO PCT/US2002/016306 patent/WO2002096415A2/en active IP Right Grant
- 2002-05-22 JP JP2002592925A patent/JP2004532868A/ja active Pending
- 2002-05-22 EP EP02774113A patent/EP1392287B8/en not_active Expired - Lifetime
- 2002-05-22 MX MXPA03010843A patent/MXPA03010843A/es active IP Right Grant
- 2002-05-22 AT AT02774113T patent/ATE345792T1/de not_active IP Right Cessation
- 2002-05-22 PT PT02774113T patent/PT1392287E/pt unknown
- 2002-05-22 ES ES02774113T patent/ES2275007T3/es not_active Expired - Lifetime
- 2002-05-22 DK DK02774113T patent/DK1392287T3/da active
- 2002-05-22 US US10/154,106 patent/US20030013699A1/en not_active Abandoned
- 2002-05-22 AR ARP020101893A patent/AR038956A1/es unknown
-
2007
- 2007-01-15 CY CY20071100048T patent/CY1105922T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004532868A5 (US07560449-20090714-C00011.png) | ||
ZA200305693B (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
AU680864B2 (en) | Combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorption inhibitor | |
Hoeg et al. | 3-Hydroxy-3-methylglutaryl—coenzyme A reductase inhibitors in the treatment of hypercholesterolemia | |
JP2004521894A5 (US07560449-20090714-C00011.png) | ||
RU2003126187A (ru) | Применение замещенных азетидинонов для лечения ситостеролемии | |
JP2004521893A5 (US07560449-20090714-C00011.png) | ||
CN105209465A (zh) | 治疗炎症、自身免疫性疾病和疼痛的方法 | |
JP2004517916A5 (US07560449-20090714-C00011.png) | ||
JP2005504092A5 (US07560449-20090714-C00011.png) | ||
WO2002058733B1 (en) | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
JP2005533810A (ja) | 新規な抗コレステロール組成物及びその使用方法 | |
WO2006007312A2 (en) | Co-administration of dehydroepiandrosterone (dhea) congener with pharmaceutically active agents for treating inflammation | |
PT1392287E (pt) | Métodos para tratamento de doença de alzheimer e/ou regulação dos níveis de peptídeos β amilóide num sujeito | |
ZA200402104B (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitors | |
CA2460340A1 (en) | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors | |
AU2021203189A1 (en) | Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same | |
CA2486859A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
JP2003531171A (ja) | 高脂血症関連疾患に対する組成物および治療 | |
JP2002508320A (ja) | スタチン−カルボキシアルキルエーテル配合物 | |
Su et al. | The effects of bisphosphonate on the remodeling of different irregular bones in mice | |
US20050182036A1 (en) | Medicinal composition containing an HMG-CoA reductase inhibitor | |
RU2005121909A (ru) | Профилактика и лечение болезни альцгеймера | |
CA3142325A1 (en) | Compositions and methods for treating metabolic disease | |
US20050101673A1 (en) | Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas |